期刊文献+

原发性高血压伴阵发性心房颤动药物治疗效果分析 被引量:1

原文传递
导出
摘要 目的探讨胺碘酮、厄贝沙坦、阿托伐他汀联合治疗原发性高血压伴阵发性心房颤动的临床疗效。方法将78例原发性高血压伴阵发性心房颤动随机分为胺碘酮+厄贝沙坦+阿托伐他汀组(A组)、胺碘酮+美托洛尔组(B组),每组39例,随访1a。比较2组治疗后血压、窦性心律维持率以及治疗前、治疗后12个月的左心房内径。结果在维持窦律方面A组优于B组,差异有统计学意义(P<0.05)。抑制左房扩大方面,A组优于B组,差异有统计学意义(P<0.05)。结论胺碘酮、厄贝沙坦、阿托伐他汀联合治疗原发性高血压伴阵发性心房颤动,可以更有效地减少房颤的复发,抑制左房扩大,值得临床推广应用。
作者 徐军
出处 《中国误诊学杂志》 CAS 2011年第27期6666-6667,共2页 Chinese Journal of Misdiagnostics
  • 相关文献

参考文献4

二级参考文献23

  • 1Wolf PA, Abboh RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke : the Framingham Study [ J ]. Stroke, 1991,2 (8) :983 -988.
  • 2Benjamin E J, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death : the Framingham heart [J]. Circulation, 1998,98 (10) :946 - 952.
  • 3Engelmann M, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation[ J]. Eur Heart J ,2005,26:2083 - 2092.
  • 4Walraven C,Hart RG,Singer DE,et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation An individual patient meta-analysis. JAMA, 2002,288: 2441-2448.
  • 5Go AS,Hylek EM,Chang Y,et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA,2003,290:2685 -2692.
  • 6Wang TJ,Massaro JM,Levy D,et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community The Framingham Heart Study.JAMA ,2003,290:1049-1056.
  • 7SPORTIF Ⅲ investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF Ⅲ): randomized controlled trial. Lancet, 2003, 362: 1691-1698.
  • 8Wattigney WA,Mensah GA,Croft JB. Increasing trends in hospitalization for atrial fibrillation in the united states, 1985 through 1999 implications for primary prevention. Circulation,2003,108 :711-716.
  • 9Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet, 2000,356:1789-1794.
  • 10Louis A, Cleland JG, Crabbe S, et al. Clinical trials update:CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology,2001. Eur J Heart Fail ,2001,3:381-387.

共引文献121

同被引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部